患者腫瘍組織移植 (PDX) モデル市場：タイプ別、腫瘍タイプ別、用途別、エンドユーザー別-2023～2030年の世界予測

患者腫瘍組織移植 (PDX) モデルの世界市場は大きく成長し、2023年には2億2,226万米ドル、CAGR14.47%と予測され、2030年には5億7,999万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の患者腫瘍組織移植 (PDX) モデル市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.患者腫瘍組織移植 (PDX) モデルの世界市場規模および予測は？

2.予測期間中、世界の患者腫瘍組織移植 (PDX) モデル市場を形成するCOVID-19の阻害要因と影響は？

3.患者腫瘍組織移植 (PDX) モデルの世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.患者腫瘍組織移植 (PDX) モデルの世界市場における競争戦略は？

5.患者腫瘍組織移植 (PDX) モデルの世界市場における技術動向と規制の枠組みは？

6.患者腫瘍組織移植 (PDX) モデルの世界市場における主要ベンダーの市場シェアは？

7.患者腫瘍組織移植 (PDX) モデルの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 個別化医療への需要の高まり
    • 腫瘍学と前臨床開発
    • 政府による前臨床プログラムと文書の作成における申請者に対する資金提供とサービスの計画
  • 抑制要因
    • パーソナライズされたPDXモデルのコストが高い
  • 機会
    • 人間化されたPDXモデルに対する需要の高まり
    • 医薬品研究開発の成長
  • 課題
    • がん研究における動物の倫理的使用に関する厳格なガイドライン
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 患者腫瘍組織移植 (PDX) モデル市場：タイプ別

• イントロダクション
• マウスモデル
• ラットモデル

第7章 患者腫瘍組織移植 (PDX) モデル市場：腫瘍タイプ別

• イントロダクション
• 消化管腫瘍モデル
• 婦人科腫瘍モデル
• 血液腫瘍モデル
• 呼吸器腫瘍モデル
• 泌尿器科腫瘍モデル

第8章 患者腫瘍組織移植 (PDX) モデル市場：用途別

• イントロダクション
• がんの基礎調査
• バイオマーカー分析
• 前臨床薬の開発

第9章 患者腫瘍組織移植 (PDX) モデル市場：エンドユーザー別

• イントロダクション
• 学術・研究機関
• 受託研究機関
• 製薬およびバイオテクノロジー企業

第10章 南北アメリカの患者腫瘍組織移植 (PDX) モデル市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の患者腫瘍組織移植 (PDX) モデル市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの患者腫瘍組織移植 (PDX) モデル市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
• FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2022 VS 2030
• FIGURE 3. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2022 VS 2030 (%)
• FIGURE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 7. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
• FIGURE 8. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
• FIGURE 10. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 8. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS , BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 190. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 191. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET LICENSE & PRICING

The Global Patient-Derived Xenograft/PDX Model Market is forecasted to grow significantly, with a projected USD 222.26 million in 2023 at a CAGR of 14.47% and expected to reach a staggering USD 574.99 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Patient-Derived Xenograft/PDX Model Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Patient-Derived Xenograft/PDX Model Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Mice Models and Rat Models. The Mice Models is projected to witness significant market share during forecast period.

Based on Tumor Type, market is studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Respiratory Tumor Models, and Urological Tumor Models. The Gynecological Tumor Models is projected to witness significant market share during forecast period.

Based on Application, market is studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development. The Basic Cancer Research is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutions, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies. The Academic & Research Institutions is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Patient-Derived Xenograft/PDX Model Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Patient-Derived Xenograft/PDX Model Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Patient-Derived Xenograft/PDX Model Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Patient-Derived Xenograft/PDX Model Market?

4. What is the competitive strategic window for opportunities in the Global Patient-Derived Xenograft/PDX Model Market?

5. What are the technology trends and regulatory frameworks in the Global Patient-Derived Xenograft/PDX Model Market?

6. What is the market share of the leading vendors in the Global Patient-Derived Xenograft/PDX Model Market?

7. What modes and strategic moves are considered suitable for entering the Global Patient-Derived Xenograft/PDX Model Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Patient-Derived Xenograft/PDX Model Market, by Type, 2022 vs 2030
• 4.3. Patient-Derived Xenograft/PDX Model Market, by Tumor Type, 2022 vs 2030
• 4.4. Patient-Derived Xenograft/PDX Model Market, by Application, 2022 vs 2030
• 4.5. Patient-Derived Xenograft/PDX Model Market, by End-User, 2022 vs 2030
• 4.6. Patient-Derived Xenograft/PDX Model Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for personalized medicine
    • 5.1.1.2. Oncology and preclinical development
    • 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of personalized PDX model
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising demand for humanized PDX Model
    • 5.1.3.2. Growth in pharma R&D
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Patient-Derived Xenograft/PDX Model Market, by Type

• 6.1. Introduction
• 6.2. Mice Models
• 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

• 7.1. Introduction
• 7.2. Gastrointestinal Tumor Models
• 7.3. Gynecological Tumor Models
• 7.4. Hematological Tumor Models
• 7.5. Respiratory Tumor Models
• 7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

• 8.1. Introduction
• 8.2. Basic Cancer Research
• 8.3. Biomarker Analysis
• 8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

• 9.1. Introduction
• 9.2. Academic & Research Institutions
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing